Centene Corporation (NYSE:CNC) is a prominent player in the healthcare sector, primarily focusing on providing services to government-sponsored healthcare programs. The company operates within the Zacks Medical - HMOs industry, competing with other major health insurers. On February 6, 2026, Centene reported its earnings, revealing an earnings per share (EPS) of -$1.19, which was slightly better than the estimated EPS of -$1.22.
Centene's revenue for the quarter ending December 2025 was $49.73 billion, surpassing the estimated $48.41 billion. This represents a significant 21.9% increase from the previous year's $40.81 billion, as highlighted by Zacks. The company has consistently exceeded consensus revenue estimates over the past four quarters, demonstrating its ability to outperform market expectations.
Despite reporting a quarterly loss of $1.19 per share, Centene's EPS exceeded the Zacks Consensus Estimate of a $1.25 loss, marking a positive surprise of 4.76%. This is a notable change from the previous year's earnings of $0.80 per share. Over the past four quarters, Centene has exceeded consensus EPS estimates three times, showcasing its resilience in a challenging market.
For the full year 2025, Centene reported a GAAP diluted loss per share of $13.53, while the adjusted diluted earnings per share stood at $2.08. Looking ahead, the company projects adjusted diluted earnings per share to exceed $3.00 in 2026. Centene's Health Benefits Ratio (HBR) for the fourth quarter of 2025 was 94.3%, with improvements in the Medicaid HBR, indicating a positive trend in its healthcare services.
Centene's financial metrics, such as a price-to-earnings (P/E) ratio of -3.55 and a price-to-sales ratio of 0.10, reflect its current negative earnings situation. However, the company's debt-to-equity ratio of 0.84 suggests a moderate level of debt compared to equity. With a current ratio of 1.08, Centene maintains a reasonable level of short-term financial health, indicating its ability to meet current liabilities.
